• Veracyte, ticker NasdaqGM:VCYT, plans to present more than 15 abstracts from its urology portfolio at the 2026 ASCO Genitourinary Cancers Symposium.
• The company is preparing to launch its TrueMRD test for muscle invasive bladder cancer and continues to build out its broader genomic testing offerings.

Veracyte enters this news cycle with its shares at $35.72 and a mixed return profile, including a 50.7% gain over three years alongside a 15.7% decline year to date and a 12.0% decline over the past month. For investors tracking diagnostics names, this combination of recent share price pressure and longer term compounding can highlight why fresh clinical data and product launches may be important signals.

The upcoming TrueMRD launch and expanded urology data set indicate active product pipeline work that could influence how the business evolves from here. As you assess NasdaqGM:VCYT, this type of clinical and commercial progress may matter as much as the usual quarterly numbers, particularly for investors focused on cancer testing platforms and their role in patient care.

Stay updated on the most important news stories for Veracyte by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Veracyte.

Quick Assessment

• ✅ Price vs Analyst Target: At US$35.72 versus an analyst target of US$47.67, the price sits about 25% below consensus expectations.
• ✅ Simply Wall St Valuation: Simply Wall St currently flags Veracyte as trading around 36.8% below its estimated fair value.
• ❌ Recent Momentum: The 30 day return of roughly 12% decline shows recent selling pressure despite the upcoming ASCO data and TrueMRD launch.

There is only one way to know the right time to buy, sell or hold Veracyte. Head to Simply Wall St's company report for the latest analysis of Veracyte's Fair Value..

Key Considerations

• 📊 The ASCO genitourinary presentations and TrueMRD launch keep the urology franchise in focus, which matters for how you frame Veracyte as a cancer testing platform play.
• 📊 Keep an eye on adoption metrics for TrueMRD, urology test volumes and how these feed into revenue, margins and the current P/E of about 93x.
• ⚠️ One flagged risk is that large one off items affect reported earnings quality, so you may want to separate recurring performance from non recurring items when reviewing results tied to this news.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Veracyte analysis. Alternatively, you can check out the community page for Veracyte to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.